Ascendis Pharma A/S (NASDAQ: ASND) is a Danish biopharmaceutical company developing long-acting prodrug therapies using its TransCon™ platform. Its approved product, Skytrofa, targets growth hormone deficiency, while its pipeline includes endocrinology and oncology assets. Ascendis is a high-profile biotech growth name with late-stage catalysts and commercial ramp-up underway.
最新股票文章

平頭哥分拆上市分析:阿里巴巴AI芯片業務的結構性風險與估值框架
阿里巴巴旗下平頭哥半導體擬分拆獨立上市,摩根大通估值介於250億至620億美元。本文從業務依賴度、估值方法論、地緣政策風險及港股科技板塊估值溢價等維度,解構該交易的結構性風險與分析框架。
14:16, 11 3月 2026


